COTA Secures New Financing to Accelerate Cancer Research and Treatment Innovation


What You Should Know:

– COTA, Inc., an oncology real-world data and analytics company, announced its latest financing by an investment fund managed by Deerfield Management and additional capital from existing investors.

– The company will use this new funding to further expand its real-world data platform and services in order to drive more efficient and inclusive drug development in oncology.

– Perella Weinberg Partners LP served as exclusive financial advisor and Goodwin Procter LLP served as legal advisor to COTA on this transaction. Katten Muchin Rosenman acted as legal advisor to Deerfield Management on this transaction.

COTA Expands Services and Approaches Milestone of 2 Million Cancer Lives

Building on this latest round of financing, COTA is also announcing the expansion of its data platform to cover nearly 2 million cancer patient lives throughout the U.S. — quadrupling data access in just two years and now including emerging types of data such as full genomic data.

The company is also launching new services aimed at supporting life sciences companies with drug submissions to the Food and Drug Association (FDA) and European Medicines Agency (EMA). These new services include integrating real-world data in research and development, enabling health economics and outcomes research (HEOR), and informing market-access strategies.